Have Structure Therapeutics insiders bought shares recently?

No open-market purchase by an insider of Structure Therapeutics is on record in SEC filings since 2006.

Who is selling Structure Therapeutics stock?

No open-market sale by an insider of Structure Therapeutics (GPCR) was filed with the SEC in the last 90 days.

Do members of Congress trade GPCR?

No trade in Structure Therapeutics (GPCR) was disclosed by a member of Congress in the last 12 months.

Where does this data come from?

From official filings only: SEC Forms 4, 5 and 144 for insiders, House and Senate periodic transaction reports for Congress, SEC Form 13F for funds, Form 8-K for company events and USAspending for federal contracts. Every record on OQRO links to its source. It is public data, not investment advice.

Structure Therapeutics (GPCR) insider trading

Q: When does Structure Therapeutics report its next results?

Structure Therapeutics's next results are expected on Feb 24, 2027, before the market opens. The date can move until the company confirms it. Insiders often trade in the weeks right after results.

OQRO

Ask OQRO about this page

Ask

Want the short version?

Ask OQRO reads the filings behind this page and answers in plain words, with a link to each source.

Explain this page What did insiders at GPCR buy and sell in the last 90 days?Which members of Congress and which funds traded GPCR recently?

Ask OQRO is part of OQRO Pro. Everything else on OQRO is free.

GPCR price and disclosed activity

−42.9% (−$15.00) from Nov 13, 2025 to Nov 13, 2026 · adjusted daily closes

13F holdings, by quarter end

Insider and Congress marks sit on the trade date stated in the filing; solid is a purchase, hollow a sale. A number means several trades too close to tell apart at this range: pick a shorter range or open it for the list. Fund 13F reports are quarter-end snapshots filed up to 45 days later, so they are shown under the chart across the quarter they describe, not on the price line. Congress amounts are official ranges; mark size uses the lower bound. Past moves are not a forecast.

Insider open-market trades, filed in the last 90 daysNoneNo open-market trades reportedInsider trades →Congress trades, disclosed in the last 90 daysNoneNo House or Senate report names this stockCongress →Fund 13F changes, quarter ending Jun 30, 20264 added · 4 cut8 followed funds; holdings as of the quarter end, filed by Aug 14, 2026Fund moves →Federal contracts starting in the last 12 monthsNoneNo award found for this companyContracts →

Counts of filings OQRO holds, by the date each was filed or the award started. Every figure links to its official SEC, House, Senate or USAspending record.

Pharmaceutical Preparations company based in South San Francisco, Ca.

Last 12 months

−42.9%

S&P 500 +12.3% over the same dates

Market value

$4.28B

Close of Nov 13, 2026 × shares outstanding (per ADS where it applies)

S&P 500 +12.3% over the same dates. Prices adjusted for splits and dividends.

Short interest: 5.93M shares sold short (2.8% of shares outstanding), −17.1% vs the previous count, 6.5 days of normal trading to buy them back. FINRA, as of Oct 30, 2026.

Latest results: quarter ending Jun 30, 2026

Revenue

—

Free cash flow, last 12 months

−$225M

This quarter −$120M, a year earlier −$54.8M

Net debt

—

Debt —, cash $273M, at Jun 30, 2026

Net income, last 12 months

−$215M

From the company's own quarterly and annual reports to the SEC. Free cash flow (cash from operations minus capital spending), net debt (debt minus cash) and 12-month totals are calculated by OQRO. Production rates, deliveries, approvals and guidance are in its results announcement of Nov 9, 2026.

When insiders usually buy

Last results

Nov 9, 2026

Within the 30 days after it, until Dec 9, 2026

Next results, expected

Feb 24, 2027

before the market opens; the date can move until the company confirms it

Purchases after results

Not enough history

From Structure Therapeutics's own results filings (8-K Item 2.02) and its insiders' Forms 4 and 5. Many companies only let insiders trade in a period after results; OQRO does not know Structure Therapeutics's policy and only shows the pattern in the filings. A purchase made long after results, at a company whose insiders usually buy right after them, is marked “Bought outside the usual window”.

Holders above 5%

FMR LLC
Schedule 13G: passive · filed Nov 5, 2026 · 32.1M shares
15%

Anyone owning more than 5% must file within days. Structured filings have existed since December 2024, so older stakes that were never amended may be missing.

Latest

See everything

Fund moves

4.74MShares reported · +460K vs prior quarter

Filed 3mo ago

6 tracked managers disclosed the same change for Q2 2026. From a 13F filed Aug 14, 2026 covering holdings at Jun 30, 2026 — a quarter-end snapshot, not a live trade.

More Official record

Fund moves

Want the short version?

Structure Therapeutics

How this filing works

Questions about Structure Therapeutics insider trading

GPCR price and disclosed activity

Latest results: quarter ending Jun 30, 2026

When insiders usually buy

Holders above 5%

Latest

4.74MShares reported · +460K vs prior quarter

2.21MShares reported · +734K vs prior quarter

1.61MShares reported

545KPrior-quarter shares · no longer reported

1.09MShares reported · +318K vs prior quarter

Other Pharmaceutical Preparations companies

When insiders usually buy

Holders above 5%